Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01048034
What this trial is testing

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Nordic MDS Group 30
Testing effectiveness (Phase 2)Looking for participantsNCT05308264
What this trial is testing

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Who this might be right for
Low Risk Myelodysplastic Syndromes
Rigel Pharmaceuticals 86
Testing effectiveness (Phase 2)WithdrawnNCT05766514
What this trial is testing

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
University of Florida
Early research (Phase 1)Study completedNCT00916227
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 45
Testing effectiveness (Phase 2)Ended earlyNCT05178342
What this trial is testing

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Who this might be right for
Myelodysplastic SyndromesAnemia
University of Leipzig 38
Large-scale testing (Phase 3)Active Not RecruitingNCT05883956
What this trial is testing

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, Chronic+1 more
Otsuka Australia Pharmaceutical Pty Ltd 13
Post-approval studies (Phase 4)Study completedNCT00452660
What this trial is testing

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Who this might be right for
Myelodysplastic Syndrome
Wolfson Medical Center 21
Large-scale testing (Phase 3)Ended earlyNCT03263091
What this trial is testing

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Who this might be right for
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)Anemia
Kyntra Bio 184
Testing effectiveness (Phase 2)Ended earlyNCT01034657
What this trial is testing

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 34
Testing effectiveness (Phase 2)Looking for participantsNCT04419649
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesCytopenia
Takeda 160
Testing effectiveness (Phase 2)Study completedNCT00910858
What this trial is testing

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Who this might be right for
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Celgene Corporation 40
Early research (Phase 1)Looking for participantsNCT06670222
What this trial is testing

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Low-risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 24
Early research (Phase 1)WithdrawnNCT04176653
What this trial is testing

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Who this might be right for
Non-transfusion-dependent ThalassemiaLow Risk Myelodysplastic Syndrome
Silence Therapeutics plc
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661
What this trial is testing

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation 289
Testing effectiveness (Phase 2)Study completedNCT00053001
What this trial is testing

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Who this might be right for
AnemiaLeukemiaMyelodysplastic Syndromes+1 more
Fallon Clinic
Testing effectiveness (Phase 2)Study completedNCT03011034
What this trial is testing

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Who this might be right for
Myelodysplastic Syndromes
Janssen Research & Development, LLC 34
Testing effectiveness (Phase 2)Study completedNCT02477631
What this trial is testing

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Who this might be right for
Myelodysplastic Syndrome With Low-grade LesionsIron Overload Due to Repeated Red Blood Cell Transfusions
Sheba Medical Center 19
Large-scale testing (Phase 3)Active Not RecruitingNCT05949684
What this trial is testing

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Who this might be right for
Myelodysplastic Syndromes
Bristol-Myers Squibb 402
Testing effectiveness (Phase 2)Study completedNCT00095264
What this trial is testing

Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Amgen 209
Large-scale testing (Phase 3)Study completedNCT01243476
What this trial is testing

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Fundación General de la Universidad de Salamanca 61
Next Page